Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ICD-Cancer

Financiado

Immunogenic cell death (ICD) in the cancer-immune dialogue

The success of most if not all anticancer treatments depends on the (re)activation of immunosurveillance, as this has been documented for several therapeutic modalities, not only immunotherapy, but also chemotherapy, targeted ther... ver más

31/12/2027

UPCité

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITE PARIS CITE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-03

ERC-2021-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

UPCité

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TrojanDC TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IM... 75K€ Cerrado

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

PDT-NEO-immunother Generation of tumor neoantigens with photodynamic therapy: a... 176K€ Cerrado

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2022-12-03
Fecha Fin: 2027-12-31

Líder del proyecto

UNIVERSITE PARIS CITE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto The success of most if not all anticancer treatments depends on the (re)activation of immunosurveillance, as this has been documented for several therapeutic modalities, not only immunotherapy, but also chemotherapy, targeted therapy and radiotherapy. In response to antineoplastic drugs, malignant cells can undergo immunogenic cell death (ICD), thus exposing and releasing danger signals that act on pattern recognition receptors expressed by immune cells, in particular dendritic cells (DCs), to trigger the first steps of a therapeutically relevant anticancer immune response. Based on solid preliminary data and novel methodological approaches, we propose to obtain fundamental insights into the physicochemical properties and molecular mode of action of pharmacological ICD inducers (Objective 1), to create chemical-genetic systems for synthetic ICD induction for the study of ICD effects on the immune system without perturbation by pleiotropic anticancer drugs (Objective 2) and to identify new ICD-relevant immune checkpoints acting at the level of DCs (Objective 3). We will use this knowledge to generate an integrated view of the cancer-immune dialogue ignited, on one side, by malignant cells succumbing to ICD and, on the other side, DCs perceiving ICD, hence developing optimal strategies for the stimulation of tumor immunosurveillance (Objective 4). The concept of ICD has already been useful for patient-relevant biomarker discovery, drug development and trial design, strongly suggesting that a deeper exploration of this phenomenon will yield clinically relevant information.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores